Prognostic value of some inflammatory markers in patients with lymphoma.

Nahla Hamed Anber,Shaker A Mousa,Sameh S Shamaa,Noureldien H.E Darwish,Ahmed H El-Sebaie

doi:10.1042/bsr20182174

Nahla Hamed Anber, Shaker A Mousa + Show 3 more

Open Access

https://doi.org/10.1042/bsr20182174

Copy DOI

Abstract

Background: Lymphoma is a group of blood cell tumors which develop from lymphocytes. The main forms of lymphoma are Hodgkin lymphoma (HL) and non-HL (NHL). Cytokines may contribute to lymphoma and they are related to risk NHL and HL. Aim: Assessment of the serum level of certain inflammatory markers as complementary indicators to confirm diagnosis of lymphoma patients that may be subjected to more invasive biopsy methods. Method: The serum levels of interleukin (IL)-1β (IL-1β), IL-6, IL-10, tumor necrosis factor-α (TNF-α), monocyte chemotactic protein-1 (MCP-1), granulocyte colony-stimulating factor (G-CSF), and eotaxin were assessed by Bio-Plex Pro assays in 81 lymphoma patients and 44 NHL and 37 HL patients before and after chemotherapy treatment as well as 20 healthy persons as a control group. Results: Lymphoma patients showed significantly raised marker levels before treatment and significantly reduced levels related to pre-treatment and controls of post-treatment for most of the markers. MCP-1 reported the highest diagnostic accuracy. G-CSF significantly raised pre-treatment and TNF-α. MCP-1 significantly increased in post treated HL compared with NHL. In order to distinguish HL from NHL, G-CSF reported the highest diagnostic accuracy. NHL patients reported complete remission (CR) and those who reported stable disease (SD) and progressive disease (PD) represented 25% and 38% respectively compared with 16% and 27% of HL patients, while partial remission (PR) of HL patients were 56% compared with 36% of NHL patients. Conclusion: Most of the markers were significantly increased in pre-treatment but significantly decreased post-treatment. However, it was not considerably enough to get better prognosis of the disease. Elevated serum levels of inflammatory markers correlate with disease severity and low benefit from treatment.

Highlights

In Egypt, lymphoma represents the most common hematologic malignancy up to 8.4% of all diagnosed cancer types every year
Inflammatory marker profiles may be used as complementary indicators to confirm clinical and laboratory diagnosis results of lymphoma patients that may be subjected to more invasive biopsy methods depending on their cytokine profile
Eotaxin serum levels reflected significant (P

Summary

Introduction

In Egypt, lymphoma represents the most common hematologic malignancy up to 8.4% of all diagnosed cancer types every year. Multiple area of hypoxia is a common feature of solid tumors and many markers are produced in the area of hypoxia such as monocyte chemotactic protein-1 (MCP-1), granulocyte colony-stimulating factor (G-CSF), and eotaxin. These markers are potent chemokines that are chemotactic toward the monocytes in nearby blood vessels [5]. Method: The serum levels of interleukin (IL)-1β (IL-1β), IL-6, IL-10, tumor necrosis factor-α (TNF-α), monocyte chemotactic protein-1 (MCP-1), granulocyte colony-stimulating factor (G-CSF), and eotaxin were assessed by Bio-Plex Pro assays in 81 lymphoma patients and 44 NHL and 37 HL patients before and after chemotherapy treatment as well as 20 healthy persons as a control group. Elevated serum levels of inflammatory markers correlate with disease severity and low benefit from treatment

Objectives

Methods

Results

Discussion

Conclusion